Targeting Human ÃÂ²-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in TreatmentMingjun Zhang1,2, Jin He1 and Jing Yang1,3*
- *Corresponding Author:
- Jing Yang
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson
Cancer Center, Texas, USA
E-mail: [email protected]
Received date: January 21, 2016; Accepted date: February 16, 2016; Published date: February 20, 2016
Citation: Zhang M, He J, Yang J (2016) Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment. Chemo Open Access 5:190. doi: 10.4172/2167-7700.1000190
Copyright: © 2016 Zhang M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Multiple myeloma (MM) is a clonal plasma cell neoplasm that utilizes bone marrow microenvironment for survival and proliferation [1-3]. However, current therapies could rarely cure MM. The relapse or refractory aspect of the disease is commonly seen in MM patients, especially among patients with high-risk MM. In past decades, targeted immunotherapy with monoclonal antibodies (mAbs) emerged as a major new treatment modality that offered great benefits for MM patients . Different approaches, aimed at finding potential mAbbased therapeutics for this disease including identification of alternative, or novel, target antigens , conjugation of mAbs with classic or novel drugs , and generation of chimeric antigen receptor T cells with specific mAbs , have been developed by scientists. Recently, our group has generated the mAbs that work directly against human β2-microglobulin (β2M) both in vitro and in the mouse experiments, and has demonstrated that β2M is a potential target for MM treatment .